| Name | Title | Contact Details |
|---|
Axiom Imaging of Las Vegas is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AES-Chemunex is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Flowers Chemical Laboratories is a Altamonte Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
siParadigm is committed to create sustainable value by delivering outstanding services to our clients to help them meet the challenges of today’s changing healthcare environment. Our team is diligent in improving the quality of healthcare by providing the highest quality of laboratory testing and unmatched Turn-Around-Time (TAT). We will strive to meet these objectives by continuing to grow and adapt to consistently meet the needs of our patients, clients, and health system.
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.